Imagine you have tried everything. You have been through the antidepressants, the talking therapies, the adjustments to lifestyle and sleep and diet that well-meaning clinicians suggest. Nothing has worked. You are still depressed, still suffering, and still looking for something that will help. Then you read the headlines. Psychedelics, they say, are transforming the treatment of mental illness. Magic mushrooms are producing breakthroughs. Researchers are excited. Regulators are responding. But before relief feels finally within reach, one question demands an honest answer: is psychedelic therapy safe?
This is the story being told to some of the most vulnerable people in the country. So is psychedelic therapy safe? And is it effective? Those questions deserve honest answers.
A New Way to Approve a Drug
There has always been a formal process for deciding whether a medicine is safe and effective enough to give to patients. Regulators designed it to be slow and demanding. Treatments have to prove themselves through rigorous clinical trials before they reach the public. That process exists because the history of medicine is also a history of treatments that seemed promising and turned out to be harmful.
Something different is happening with psychedelics. Rather than evidence, a combination of advocacy, media attention, and commercial investment is driving their legitimacy, and building its own kind of momentum. Call it the “vote for medicine” model: if enough people believe in a treatment strongly enough and push hard enough for access, the evidential bar quietly drops to accommodate them.
In 2023, Australia’s Therapeutic Goods Administration rescheduled psilocybin and MDMA, making them more accessible as therapeutic medicines. The decision came after years of optimistic media coverage and intense lobbying from researchers, patient groups, and a rapidly growing psychedelic industry. Researcher Jack Wilson, a research fellow at the University of Sydney, noted the parallel with medicinal cannabis: “Medicinal cannabis originally had many hoops to jump through, like psychedelic-assisted therapies do in Australia now. But in 2021, things streamlined and it became much easier to access.” His concern is that psychedelics are heading down the same road, with access expanding before the evidence is ready to support it.
What Three New Studies Found
This week, three studies landed that should prompt serious reflection from everyone involved in that push.
Two studies published in JAMA Psychiatry examined the effectiveness of psychedelics against traditional antidepressants. The first reviewed clinical trials across LSD, psilocybin, peyote, and ayahuasca, and found that none of these performed better than conventional antidepressants for treating depression. The second, a clinical trial of psilocybin specifically, returned inconclusive results. In that trial, 86 per cent of participants could accurately identify whether they had received the drug or a placebo. When patients know they have taken a drug they have been told is revolutionary, the results cannot be cleanly separated from the power of expectation.
A third study, published in The Lancet, reviewed 54 clinical trials on cannabis and cannabinoids and found no evidence they effectively treat depression, anxiety, or PTSD. Doctors in Australia prescribe cannabis most commonly for exactly those three conditions. More striking still: across all 54 trials, not one randomised controlled study had looked specifically at cannabis for depression. “Those three are quite important because they’re three of the leading mental health conditions for which they’re prescribed,” Wilson said. “In fact, there was actually not a single randomised controlled trial that examined cannabis use for the treatment of depression, which is really concerning.
Randomised controlled trials are not a bureaucratic preference. They are the most reliable tool medicine has for distinguishing treatments that actually work from treatments that people believe work. Their absence is a serious problem, not a detail.
The Research Is Weaker Than the Headlines Suggest
The problem runs deeper than three studies. Researchers Michael van Elk and Eiko Fried at Leiden University have documented ten methodological problems that recur across psychedelic research. These are not obscure statistical concerns. They are fundamental failures that undermine the reliability of findings across the field.
Many studies have no control group at all. Without a comparison group, a result is almost meaningless. Van Elk and Fried highlight a 27-person psilocybin study in which 60 per cent of participants were no longer depressed after a year. That sounds encouraging until you learn that other research shows more than half of people with depression would recover without treatment within the same period. The study could not distinguish the drug’s effect from natural recovery.
Financial conflicts of interest pervade the field. Pharmaceutical companies fund most psychedelic research, and researchers with those ties are five times more likely to report a positive drug effect than those without them. Researchers also routinely switch outcomes: when a drug fails on its pre-registered measure, they quietly swap in a new one and present it as though it were always the point. One ketamine study found that only two of fourteen patients showed lower suicidal ideation at three months. The study’s title still called it “sustained” improvement.
Sam Moreton, a lecturer in psychology at the University of Wollongong, said what the data supports: “The hype around psychedelic therapy has consistently run ahead of what the evidence actually supports. There are good theoretical reasons to think psychedelic-assisted therapy could help with depression and other mental health conditions, and I think it’s absolutely worth researching properly. But the field has serious methodological problems that have been well documented.”
The honest summary is that we do not yet know whether these treatments work, for whom, under what conditions, or at what risk. Asking whether psychedelic therapy is safe is not a fringe concern. It is the most basic question medicine requires us to answer before widespread use. Science cannot yet provide that answer.
What Happens Outside the Trial
There is a further gap that rarely makes the headlines. When people ask whether psychedelic therapy is safe, clinical trials always qualify their answer: safe under these conditions, with these patients, in this setting. Trials run as controlled environments. Researchers screen participants carefully, excluding anyone with histories of psychosis, suicidality, or multiple diagnoses. Staff measure every dose. Trained therapists stay present throughout. When things go wrong, help stands ready.
This is not how most people will encounter these drugs if access continues to expand.
A Canadian study published in the Canadian Medical Association Journal examined what happens to people who present in emergency rooms after severe psychedelic reactions. Researchers found these individuals were 2.6 times more likely to die within five years. Suicide was the most common cause of early death in this group, followed by unintentional drug poisoning. Dr Daniel Myran, the study’s lead author, was direct about the gap between clinical settings and real-world use: “You’re in a controlled environment with help standing by [in trials]. That is very different from the experience for people outside of these trials.”
Dr Charles Raison, a psychiatry professor and expert in psychedelic studies at the University of Wisconsin, noted that adverse outcomes sometimes persisted well beyond the initial episode: “Maybe one in 20 people report having ongoing difficulties they ascribe to the psychedelic experience. A year later, they say, ‘I had an experience so distressing it messed up my ability to function, alienated me from my family, or gave me PTSD.'”
The patients most likely to be screened out of clinical trials are also, not coincidentally, many of the patients most desperate for help. The people who read optimistic headlines are not always the people who would qualify for a supervised trial.
The Harm in False Hope
There is a version of this argument that sounds uncompassionate, so let us be clear about what this argument actually says. No one is arguing that psychedelics can never help anyone. Some researchers, including Professor Susan Rossell of Swinburne University of Technology, believe that properly conducted trials, with rigorous psychotherapeutic support alongside drug treatment, may eventually produce stronger evidence in their favour. That view is worth taking seriously. But “is psychedelic therapy safe” is not a question that goodwill and optimism can answer. Only evidence can.
But Professor Rossell also said this: “We’ve had a couple of people come through our programs and actually relapsed. So I guess we could say that we’ve made them worse, which is awful.”
This is a researcher who believes in the work, running trials with proper supervision, still producing outcomes that harmed people. The question of what happens to patients outside that level of care, chasing a treatment promoted with confidence the evidence does not yet support, is not a small one.
When desperate people are given inflated hope, they do not just feel disappointed when the treatment fails. Worse, they may delay pursuing treatments with stronger evidence. Unregulated access without proper support becomes more likely. And some emerge worse than they went in, with fewer resources and less trust in the health system that was supposed to help them.
Lowering evidential standards in the name of compassion is not compassionate. It is a way of making the people pushing for access feel that they are doing something, while the patients themselves carry the risk.
The Standard Worth Keeping
Caution here is not a stance against hope or research. It is a demand for honesty. Is psychedelic therapy safe? Right now, nobody can reliably answer that question. The science remains immature, methodologically compromised, and unable to support the claims advocates make on its behalf. The patients most likely to seek these treatments rank among the most vulnerable people in the health system. They deserve straight answers about what we know, what we don’t, and what dangers they face.
Good medicine has always had to hold the line between what patients want to hear and what the evidence actually shows. That line is not a bureaucratic inconvenience. It is the thing that separates medicine from false hope.
The vote for medicine model feels generous. In practice, it transfers risk onto the people least equipped to bear it. That is not a reform. It is a failure.
(Source: WRD News)
